Search for a trial

An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy

The main aim of this study is to find out if the continuation of bevacizumab, in addition to standard 2nd & 3rd -line treatment, can help patients with NSCLC that has progressed to live longer. The study also aims to find out if continued…

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC) (CLDK378A2112)

Primary: To assess the steady-state PK of 450 mg or 600 mg ceritinib taken daily with a low-fat meal as compared with that of 750 mg ceritinib taken daily in the fasted state in patients with metastatic ALK-positive NSCLC.Secondary: Overall response…

Brown adipose tissue activity and energy metabolism in cachexia induced by cancer or chronic disease

To study BAT activity and energy metabolism in patients with cachexia induced by cancer or chronic disease.

A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Primary Objective* The primary objective of this study is to compare the confirmed objective response rate (ORR) by Week 19 following treatment with bevacizumab-Pfizer in combination with paclitaxel and carboplatin to bevacizumab-EU plus paclitaxel…

A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib

The primary objective of this study is to compare PFS with LY2875358 plus erlotinib therapy with erlotinibmonotherapy as first-line treatment in metastatic NSCLC patients with activating EGFR mutations who havedisease control after an 8-week lead-in…

eNose Analysis of Air Sampled by Bronchoscopy.

We hypothesize that a diagnostic algorithm based on tumor site-specific VOCs enables the discrimination of lung cancer patients and controls compared to exhaled breath sampling.We aim to test this hypothesis by conducting a cross-sectional…

Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT):
part 4. Diagnostic value of the eNose in Head and Neck Cancer

The primary objective of this study is:to examine the difference in VOC pattern of exhaled air (breathprint) between patients with histology-confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC) and healthy controls.The secondary…

Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT):
part 1. Differences in smellprints between patients with lung cancer and breast cancer

Primairy objective: we will examine the difference in VOC pattern of exhaled air between patients with histology-confirmed diagnoses of non small cell lung cancer vs breast cancer. Secundairy objective: a. to confirm the potential of the electronic…

A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy

The primary objective is to demonstrate superiority in overall survival of amrubicin (40 mg/m2 administered as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course) compared with topotecan hydrochloride (…

A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Primary Objective:Part 1: To identify a dose of AMG 479 in combination with etoposide plus carboplatin and/or etoposide plus cisplatin, and of AMG 102 in combination with etoposide plus carboplatin and/or etoposide plus cisplatin that can be…

An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway.

The purpose of this prospective, multi-center, open-label, two-stage phase II study is to assessthe efficacy of BKM120, as measured by determining the PFS, in patients with pretreatedmetastatic NSCLC that exhibits PI3K pathway activation. BKM120…

A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (MEK114653)

Primary: progression-free survival in the GSK1120212-group in comparison with the docetaxel group. Secondary: safety and tolerability, response rate, duration of response, overall survival, PK.

PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC;LYMPHOMA KINASE (ALK) GENE LOCUS

To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…

A multicenter study evaluating the diagnostic value for vascular abnormalities of High Definition Bronchoscopy when combined with i-scan Imaging Technology compared to High Defintion Bronchoscopy alone

Primary objective:Determing the positive predictive value and diagnostic yield of HD+ i-scan bronchoscopy for vascular pattern detection .Secondary objectives:1. To investigate the correlation of vascular abnormalities with histology2. To…

A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment (CAUY922A2207)

Primary: Progression Free Survival (PFS) in patients treated with AUY922 versus pemetrexed or docetaxel.Secondary: Overall response rate, disease control rate, overall survival, safety and tolerability, PK.

Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus -LUNA Trial

To evaluate the efficacy of pasireotide LAR and everolimus alone or in combination in progressive patients with a well differentiated neuroendocrine tumor of the lung or thymus.

Fatigue after prophylactic cranial irradiation in stage I-III small cell lung cancer patients: is there a substrate on functional magnetic resonance imaging of the brain?

To asses the effect of PCI on the brain with functional MRI (fMRI) and diffusion tensor imaging (DTI)-MRI and assess whether there is a correlation with patient-experienced fatigue.

A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects with Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated with Chemotherapy with or without Bevacizumab

Objectives:Phase 1b: To determine the maximum tolerated dose (MTD) (up to 8mg/kg/day) through safety and tolerability of multiple doses of AMG 951 administered by intravenous (IV) infusion to subjects with NSCLC in combination with chemotherapy and…

Lobectomy for the treatment of non-small cell lung cancer (NSCLC):
video-assisted minithoracotomy (VAMT) versus muscle-sparing thoracotomy (MST)

see K1

'A one-day diagnostic track for lung cancer suspects from chest X-ray using PET-CT and subsequent multiple endoscopic investigations. (including bronchoscopy, EUS-FNA and EBUS-TBNA)'.

1. to study feasibility of a fast one-day diagnostic track including PET-CT and subsequent diagnostic/ staging investigation depending on PET-CT findings. to determine:2. the percentage of patients in which the one-day track is sufficient for…